TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07458230: Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:

Sponsor: Johns Hopkins Bloomberg School of Public Health · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 250 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,755,368

Rescue Site Savings

+$1,836,912

Unlock Full NCT07458230 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07458230 Rescue Dossier →